Abstract:Helicobacter pylori (Hp) infections pose a global health challenge demanding innovative therapeutic strategies by which to eradicate them. Urease, a key Hp virulence factor hydrolyzes urea, facilitating bacterial survival in the acidic gastric environment. In this study, a multi-methodological approach combining pharmacophore- and structure-based virtual screening, molecular dynamics simulations, and MM-GBSA calculations was employed to identify novel inhibitors for Hp urease (HpU). A refined dataset of 8,271,505 small molecules from the ZINC15 database underwent pharmacokinetic and physicochemical filtering, resulting in 16% of compounds for pharmacophore-based virtual screening. Molecular docking simulations were performed in successive stages, utilizing HTVS, SP, and XP algorithms. Subsequent energetic re-scoring with MM-GBSA identified promising candidates interacting with distinct urease variants. Lys219, a residue critical for urea catalysis at the urease binding site, can manifest in two forms, neutral (LYN) or carbamylated (KCX). Notably, the evaluated molecules demonstrated different interaction and energetic patterns in both protein variants. Further evaluation through ADMET predictions highlighted compounds with favorable pharmacological profiles, leading to the identification of 15 candidates. Molecular dynamics simulations revealed comparable structural stability to the control DJM, with candidates 5, 8 and 12 (CA5, CA8, and CA12, respectively) exhibiting the lowest binding free energies. These inhibitors suggest a chelating capacity that is crucial for urease inhibition. The analysis underscores the potential of CA5, CA8, and CA12 as novel HpU inhibitors. Finally, we compare our candidates with the chemical space of urease inhibitors finding physicochemical similarities with potent agents such as thiourea.

Urease inhibitors as potential drugs for gastric and urinary tract infections: a patent review

Lead Molecules for Targeted Urease Inhibition: An Updated Review from 2010 -2018

Synthesis and Biological Evaluation of Triazolones/oxadiazolones As Novel Urease Inhibitors

Pyridylpiperazine-based carbodithioates as urease inhibitors: synthesis and biological evaluation

New acetylphenol-based acyl thioureas broaden the scope of drug candidates for urease inhibition: synthesis, in vitro screening and in silico analysis

Studies on New Urease Inhibitors by Using Biochemical, STD-NMR Spectroscopy, and Molecular Docking Methods

Design and synthesis of novel anti-urease imidazothiazole derivatives with promising antibacterial activity against Helicobacter pylori

High-throughput Tandem-Microwell Assay for Ammonia Repositions FDA-Approved Drugs to Inhibit Helicobacter Pylori Urease

New indications for FDA-approved drugs: selective inhibition of growth of Helicobacter pylori by covalent allosteric regulation of urease

Design and discovery of urease and Helicobacter pylori inhibitors based on benzofuran/benzothiophene-sulfonate and sulfamate scaffolds for the treatment of ureolytic bacterial infections

Synthesis, Molecular Docking and Kinetic Properties of Β-Hydroxy-β-phenylpropionyl-hydroxamic Acids As Helicobacter Pylori Urease Inhibitors

Exploration of thiazine Schiff bases as promising urease inhibitors: Design, synthesis, enzyme inhibition, kinetic analysis, ADME/T evaluation, and molecular docking studies

The effect of three urease inhibitors on H. pylori viability, urease activity and urease gene expression

3-Arylpropionylhydroxamic Acid Derivatives As Helicobacter Pylori Urease Inhibitors: Synthesis, Molecular Docking and Biological Evaluation

Synthesis and biological evaluation of pyridylpiperazine hybrid derivatives as urease inhibitors

Arylamino Containing Hydroxamic Acids As Potent Urease Inhibitors for the Treatment of Helicobacter Pylori Infection.

Synthesis and Evaluation of N-analogs of 1,2-Diarylethane As Helicobacter Pylori Urease Inhibitors.

Synthesis and Biological Evaluation of Dithiobisacetamides as Novel Urease Inhibitors

Molecular design of hydroxamic acid-based derivatives as urease inhibitors of Helicobacter pylori

A Multi-Methodological Approach from Virtual Screening and ADME to Molecular Dynamics Simulations

Rational design and in vitro testing of new urease inhibitors to prevent urinary catheter blockage